Latest CanVECTOR News
August 24, 2016
The Network News August edition available now

Find it on the News & Events page!

Read More
Article Thumbnail
June 17, 2016
Dr. David Anderson interviewed by CTV on EPCAT II study

CanVECTOR member David Anderson was recently interviewed by CTV Atlantic about the EPCAT II study.

 

Read More
Article Thumbnail
February 17, 2016
Pilot Trials call for proposals launched

Go to our Clinical Trials and Shared Platforms page (under Research > Science Platforms) to learn more! 

Read More

Annual incidence of

2/1000

population per year

Cost of VTE: at least

$600m

CAD a year

VTE recurrence

5-10%

per year

Chronic thromboembolic pulmonary hypertension

3-4%

after PE

Pulmonary Embolism
leads to the hospitalization
or death of over

30,000

Canadians every year

VTE leads to significant

long-term
costs

in the form of chronic complications of VTE

Post-thrombotic syndrome

20-40%

after DVT

Adverse effects and

burden of anticoagulant therapy

Upcoming Events

Monday, September 12, 2016 at 12:00 PM

CanVECTOR Investigators' Group Meeting

Tuesday, September 13, 2016 at 08:00 AM

Scientific Steering Committee Meeting

Thursday, October 13, 2016

World Thrombosis Day

Evidence Pearls on VTE

Evidence Pearls on VTE RSS Feed
Diagnostic characteristics of lower limb venous compression ultrasonography in suspected pulmonary embolism: a meta-analysis.
Aug 28, 2016
Tranexamic Acid Administration in Primary Total Hip Arthroplasty: A Randomized Controlled Trial of Intravenous Combined with Topical Versus Single-Dose Intravenous Administration.
Aug 28, 2016
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Aug 28, 2016

Twitter